Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.

Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN.

J Natl Cancer Inst. 2019 Oct 31. pii: djz215. doi: 10.1093/jnci/djz215. [Epub ahead of print]

PMID:
31693129
2.

Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma.

Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL.

Clin Cancer Res. 2019 Feb 15;25(4):1206-1215. doi: 10.1158/1078-0432.CCR-18-2665. Epub 2018 Nov 6.

PMID:
30401687
3.

Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study.

Keegan THM, Kushi LH, Li Q, Brunson A, Chawla X, Chew HK, Malogolowkin M, Wun T.

J Cancer Surviv. 2018 Jun;12(3):388-397. doi: 10.1007/s11764-018-0678-8. Epub 2018 Feb 9.

PMID:
29427203
4.

Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer.

Parikh M, Galkin M, Brunson A, Keegan T, Chew HK.

Cancer Treat Res Commun. 2018;16:38-44. doi: 10.1016/j.ctarc.2018.06.001. Epub 2018 Jun 13.

PMID:
31299001
5.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

6.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN.

J Clin Oncol. 2015 Jan 1;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. Epub 2014 Nov 24.

8.

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer.

Chew HK, Schwartzberg L, Badarinath S, Rubin P, Shumaker G, Daugherty J, DeSilvio M, Mahoney J.

Springerplus. 2014 Feb 22;3:108. doi: 10.1186/2193-1801-3-108. eCollection 2014.

9.

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.

Ho C, Davies AM, Sangha RS, Lau D, Lara P Jr, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR.

Invest New Drugs. 2013 Dec;31(6):1587-91. doi: 10.1007/s10637-013-0024-y. Epub 2013 Sep 8.

10.

Richter's syndrome with aberrant CD2 and CD4 expression.

Barnhard S, Pai A, Chew HK, Song JY.

J Clin Oncol. 2012 Sep 10;30(26):e243-5. doi: 10.1200/JCO.2011.40.2065. Epub 2012 May 29. No abstract available.

PMID:
22649134
11.

Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.

Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN.

Oncologist. 2012;17(2):179-87. doi: 10.1634/theoncologist.2011-0235. Epub 2012 Jan 20.

12.

Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.

Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM.

Ann Oncol. 2012 Apr;23(4):1023-9. doi: 10.1093/annonc/mdr328. Epub 2011 Jul 21.

PMID:
21778300
13.

High-mannose glycans are elevated during breast cancer progression.

de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB.

Mol Cell Proteomics. 2011 Jan;10(1):M110.002717. doi: 10.1074/mcp.M110.002717. Epub 2010 Nov 19.

14.

The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer.

Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK.

Cancer. 2010 Jun 1;116(11):2596-603. doi: 10.1002/cncr.25004.

15.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS.

J Clin Oncol. 2010 Apr 1;28(10):1671-6. doi: 10.1200/JCO.2008.20.2119. Epub 2010 Jan 11.

PMID:
20065191
16.

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS.

J Clin Oncol. 2009 May 1;27(13):2163-9. doi: 10.1200/JCO.2008.17.4839. Epub 2009 Mar 23.

17.

Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.

Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T.

Blood. 2009 Apr 23;113(17):3911-7. doi: 10.1182/blood-2008-08-175745. Epub 2008 Dec 16.

18.

Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data.

Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM.

Bioinformatics. 2009 Jan 15;25(2):251-7. doi: 10.1093/bioinformatics/btn610. Epub 2008 Dec 9.

19.

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R.

Clin Breast Cancer. 2008 Dec;8(6):511-5. doi: 10.3816/CBC.2008.n.062.

20.
21.

The incidence of venous thromboembolism among patients with primary lung cancer.

Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH.

J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17.

22.

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623.

J Clin Oncol. 2007 May 1;25(13):1677-82. Epub 2007 Apr 2.

PMID:
17404368
23.

Incidence of venous thromboembolism and the impact on survival in breast cancer patients.

Chew HK, Wun T, Harvey DJ, Zhou H, White RH.

J Clin Oncol. 2007 Jan 1;25(1):70-6.

PMID:
17194906
24.

A serum glycomics approach to breast cancer biomarkers.

Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto S.

Mol Cell Proteomics. 2007 Jan;6(1):43-55. Epub 2006 Jul 17.

25.

Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.

Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y.

Oncol Rep. 2006 May;15(5):1299-304.

PMID:
16596201
26.

Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.

Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH.

J Clin Oncol. 2006 Mar 1;24(7):1112-8.

PMID:
16505431
27.

Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Chew HK, Wun T, Harvey D, Zhou H, White RH.

Arch Intern Med. 2006 Feb 27;166(4):458-64.

PMID:
16505267
28.

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.

Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.

Clin Cancer Res. 2005 Aug 15;11(16):5920-7.

29.

Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.

White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T.

Arch Intern Med. 2005 Aug 8-22;165(15):1782-7.

PMID:
16087828
30.

Biological functions of the BRCA1 protein.

Lee WH, Chew HK, Farmer AA, Chen PL.

Breast Dis. 1998 Apr;10(1-2):11-22. No abstract available.

PMID:
15687545
31.

BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II.

Cabart P, Chew HK, Murphy S.

Oncogene. 2004 Jul 8;23(31):5316-29.

PMID:
15107825
32.

Medical management of breast cancer: today and tomorrow.

Chew HK.

Cancer Biother Radiopharm. 2002 Apr;17(2):137-49. Review.

PMID:
12030108
33.

Adjuvant therapy for breast cancer: who should get what?

Chew HK.

West J Med. 2001 Apr;174(4):284-7. Review. No abstract available.

34.

Genetic evaluation of cancer: the importance of family history.

Chew HK.

Tex Med. 2001 Feb;97(2):40-5. Review.

PMID:
11233057
35.

Emerging roles of BRCA1 in transcriptional regulation and DNA repair.

Chen Y, Lee WH, Chew HK.

J Cell Physiol. 1999 Dec;181(3):385-92. Review.

PMID:
10528224

Supplemental Content

Support Center